Ted R Mikuls1, Michael J Duryee2, Bryant R England2, Daniel R Anderson3, Michelene Hearth-Holmes2, Kaihong Su4, Kaleb Michaud5, Jeffrey B Payne6, Harlan Sayles7, Carlos Hunter8, Jacob D McGowan8, Lynell W Klassen8, Geoffrey M Thiele2. 1. Veterans Affairs (VA) Nebraska-Western Iowa Health Care System, Omaha, NE, United States; Department of Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, United States. Electronic address: tmikuls@unmc.edu. 2. Veterans Affairs (VA) Nebraska-Western Iowa Health Care System, Omaha, NE, United States; Department of Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, United States. 3. Department of Internal Medicine, Division of Cardiology, University of Nebraska Medical Center, Omaha, NE, United States. 4. Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, United States. 5. Department of Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, United States; National Data Bank for Rheumatic Diseases, Wichita, KS, United States. 6. Department of Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, United States; Department of Surgical Specialties, College of Dentistry, University of Nebraska Medical Center, Lincoln, NE. 7. Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States. 8. Department of Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, United States.
Abstract
OBJECTIVE: To compare anti-malondialdehyde-acetaldehyde (MAA) antibody concentrations between rheumatoid arthritis (RA) patients and healthy and rheumatic disease controls. METHODS: Anti-MAA antibody (IgA, IgM, IgG) was measured using ELISA and banked serum from patients with RA (n = 284), osteoarthritis (OA, n = 330), spondyloarthropathy (SpA, n = 50), and systemic lupus erythematosus (SLE, n = 88) as well as healthy controls (n = 82). Anti-MAA antibody concentrations and the frequency of positivity were compared across groups. Multivariable linear regression analysis limited to RA and OA patients (due to sample size and data availability) was used to identify factors associated with anti-MAA antibody concentrations. RESULTS: Although RA patients demonstrated among the highest circulating concentrations across isotypes, only IgA anti-MAA antibody was significantly higher than all other groups (p ≤ 0.02). Proportions (7% to 74%) of OA and SLE (less so for SpA) samples were positive for anti-MAA antibody, limiting the discriminatory capacity of anti-MAA antibody in RA (positive in 18% to 80%). In analyses limited to those with RA or OA, factors associated with higher anti-MAA antibody concentrations included RA case status, younger age (IgM), male sex (IgG), African American race (IgA, IgG) and current smoking (IgA). C-reactive protein levels and comorbidities were not associated with anti-MAA antibody concentrations. CONCLUSION: With the possible exception of the IgA isotype, serum anti-MAA antibodies measured with currently available assays do not appear to adequately discriminate RA from other rheumatic conditions. With the identification of specific proteins that are MAA-modified in diseased tissues and requisite assay refinement, anti-MAA antibody holds potential promise as a biomarker in RA.
OBJECTIVE: To compare anti-malondialdehyde-acetaldehyde (MAA) antibody concentrations between rheumatoid arthritis (RA) patients and healthy and rheumatic disease controls. METHODS: Anti-MAA antibody (IgA, IgM, IgG) was measured using ELISA and banked serum from patients with RA (n = 284), osteoarthritis (OA, n = 330), spondyloarthropathy (SpA, n = 50), and systemic lupus erythematosus (SLE, n = 88) as well as healthy controls (n = 82). Anti-MAA antibody concentrations and the frequency of positivity were compared across groups. Multivariable linear regression analysis limited to RA and OA patients (due to sample size and data availability) was used to identify factors associated with anti-MAA antibody concentrations. RESULTS: Although RApatients demonstrated among the highest circulating concentrations across isotypes, only IgA anti-MAA antibody was significantly higher than all other groups (p ≤ 0.02). Proportions (7% to 74%) of OA and SLE (less so for SpA) samples were positive for anti-MAA antibody, limiting the discriminatory capacity of anti-MAA antibody in RA (positive in 18% to 80%). In analyses limited to those with RA or OA, factors associated with higher anti-MAA antibody concentrations included RA case status, younger age (IgM), male sex (IgG), African American race (IgA, IgG) and current smoking (IgA). C-reactive protein levels and comorbidities were not associated with anti-MAA antibody concentrations. CONCLUSION: With the possible exception of the IgA isotype, serum anti-MAA antibodies measured with currently available assays do not appear to adequately discriminate RA from other rheumatic conditions. With the identification of specific proteins that are MAA-modified in diseased tissues and requisite assay refinement, anti-MAA antibody holds potential promise as a biomarker in RA.
Authors: Ted R Mikuls; Jess Edison; Elizabeth Meeshaw; Harlan Sayles; Bryant R England; Michael J Duryee; Carlos D Hunter; Lindsay B Kelmenson; Laura Kay Moss; Marie L Feser; Brandie Wagner; Mark C Parish; Kevin D Deane; Geoffrey M Thiele Journal: Arthritis Rheumatol Date: 2020-10-15 Impact factor: 10.995
Authors: Bryant R England; Michael J Duryee; Punyasha Roul; Tina D Mahajan; Namrata Singh; Jill A Poole; Dana P Ascherman; Liron Caplan; M Kristen Demoruelle; Kevin D Deane; Lynell W Klassen; Geoffrey M Thiele; Ted R Mikuls Journal: Arthritis Rheumatol Date: 2019-07-22 Impact factor: 10.995
Authors: Lorena Rodríguez-Martínez; Cristina Regueiro; Sámer Amhaz-Escanlar; Carmen Pena; Paloma Herbello-Hermelo; Antonio Moreda-Piñeiro; Javier Rodriguez-Garcia; Antonio Mera-Varela; Eva Pérez-Pampín; Antonio González Journal: Diagnostics (Basel) Date: 2022-01-29
Authors: Caroline Grönwall; Lisa Liljefors; Holger Bang; Aase H Hensvold; Monika Hansson; Linda Mathsson-Alm; Lena Israelsson; Vijay Joshua; Anna Svärd; Ragnhild Stålesen; Philip J Titcombe; Johanna Steen; Luca Piccoli; Natalia Sherina; Cyril Clavel; Elisabet Svenungsson; Iva Gunnarsson; Saedis Saevarsdottir; Alf Kastbom; Guy Serre; Lars Alfredsson; Vivianne Malmström; Johan Rönnelid; Anca I Catrina; Karin Lundberg; Lars Klareskog Journal: Front Immunol Date: 2021-05-20 Impact factor: 7.561